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Transepidermal migration of leukocytes, with resultant 
formation of microscopic or macroscopic sterile sub corneal 
pustules is a phenomenon characteristically noted in pso­
riasis and related sterile pustular dermatoses. It is natural 
to assume the presence of potent neutrophil chemotactic 
substances in the sub corneal portion of the lesional epi­
dermis, because this location is the target of the in vivo 
leukocyte chemotaxis. In fact, crude psoriasis scale extracts 
show remarkably high neutrophil chemotactic and -acti­
vating properties as compared with those of other non­
psoriatic inflammatory dermatoses. We isolated a psoriatic 
leukotactic factor (PLF) having a molecular mass of around 
12 kD, distinct from those common to other inflammatory 
changes involving the skin or those released by bacteria. 
Further analysis of PLF identified CS cleavage fragments, 
together with other chemotactic peptides, such as those 
P soriasis is a chronic scaly erythematous skin disease his­tologically characterized by epidermal acanthosis, often presenting remarkable elongation of the rete ridges and, by corresponding elongation, of dermal papillae. Such thickened psoriatic epidermis shows very rapid turn­
over associated with abnormal keratinization. Thus psoriasis has 
been deemed a dermatosis showing highly enhanced epidermal 
metabolic activity, and a large number of previous studies have 
been performed on this point. However, we should not disregard 
another important aspect of psoriatic lesions, characterized by 
prominent inflammatory changes, because enhanced epidermo­
poiesis is inducible even by simple inflammatory stimuli such as 
removal of the stratum corneum by tape stripping [1]. 
There is always a mononuclear cell infiltrate in the upper dermis 
of psoriatic lesions, even in early pinpoint lesions where the epi-
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derived from monocytes. Likewise, potent low-molecular­
mass chemotactic factors, including cell membrane lipid 
derived chemotactic factor, e.g. leukotriene B4, are also 
increased in psoriatic lesions, as in other non psoriatic in­
flammatory dermatoses. However, their activity to stim­
ulate the generation of oxygen radicals in neutrophils was 
found to be much weaker than that of PLF. 
The peripheral blood leukocytes from active psoriatic 
patients show enhanced function in chemotaxis, phago­
cytosis, active oxygen production, and enzyme release; pa­
tients' sera contain substances such as anaphylatoxins that 
activate leukocyte function. Further research is required for 
clearer understanding of the series of events resulting in 
the leukocyte chemotaxis, as well as for the elucidation of 
the background immunoregulatory mechanisms. ] Invest 
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dermis shows only nonspecific hyperplasia [2]. However, in fully 
developed psoriatic lesions, cyclic migration of polymorphonu­
clear leukocytes (PMN) occurs transepidermally from the en­
gorged blood vessels in the edematous and elongated dermal pa­
pillae to the horny layer of the overlying epidermis, eventually 
culminating in Munro's microabscesses. This characteristic his­
tologic feature has been given a term "squirting papillae" by 
Pinkus and Mehregan [1]. Moreover, secondary to excessive ir­
ritation of the skin or under influences of endogenous factors such 
as pregnancy, infections, drugs, and abrupt withdrawal of pro­
longed steroid therapy, there may occur a clinical feature of pus­
tular psoriasis that presents visible sterile pustules on diffusely 
erythematous skin. S imilar sterile subcorneal pustules are ob­
served in several other dermatoses such as pustulosis palmaris et 
plantaris (PPP), subcorneal pustular dermatosis (SPD), Reiter's 
disease, and eosinophilic pustular folliculitis (EPF). 
Are Chemical Mediators Responsible for Transepidermal 
Leukocyte Migration Demonstrable in Psoriatic Lesions? 
A number of endogenous chemotactic factors may take part in 
the development of even ordinary inflammation of the skin. To 
elucidate the pathomechanisms underlying the transepidermal 
leukocyte migration characteristic of psoriatic lesions, it is plau­
sible to presume the presence of a specific chemotactic factor that 
attracts neutrophils toward the upper portion of the lesional ep­
idermis or horny layer. The concentration of such a chemotactic 
factor should be highest at the sub corneal portion of the psoriatic 
lesioh, because it is this location that becomes the target of cyclic 
leukocyte migration. Perhaps its biologic activity is demonstrable 
even in the lesional horny layer because substances present in the 
very upper epidermal portion of psoriatic lesions are supposed to 
be pocketed in the stratum corneum in the rapidly keratinizing 
lesional skin. Additionally, scaly lesions might also be loaded with 
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exogenous chemotactic factors released by resident microbial flora. 
Hence, the lesional horny layer of psoriasis should be specifically 
rich in a certain chemotactic substance as compared with that 
from skin with other, nonspecific scaly dermatitis. 
We can display visually by using direct leukocyte attachment 
test (3) that psoriatic scale contains substances that attract and 
activate leukocytic functions. When 8-JLm cryostat specimens of 
psoriatic lesions placed on glass slides are covered with peripheral 
blood leukocyte suspensions and incubated for 45 min at 37°C, 
specific leukocyte attachment occurs in the lesional horny layer 
as illustrated in Fig 1. In our preliminary study, we encountered 
such a phenomenon in 10 (71 %) out of 14 psoriatic cases compared 
with only 4- ( 28%) of 14 control cases consisting of other inflam­
matory dermatoses. By performing the nitro blue tetrazolium test 
on such specimens we further found the formation of blackish­
blue formazan crystals in the cytoplasm of attached leukocytes, 
which indicates increased phagocytic activity and respiratory burst 
(Fig 1). It is frequently observed in organ culture of psoriatic 
lesions that the greater part of the upper epidermis degenerates 
quickly. This phenomenon could be explained by the preceding 
exposure of the lesional epidermis to toxic substances in vivo, 
i.e., toxic oxygen radicals and hydrolytic enzymes released by 
the migrating neutrophils that are activated by various chemo­
tactic factors, as shown in this test. 
How Can We Analyze in Vitro the Migration of Leuko­
cytes? Study of leukocyte chemotaxis has been greatly facilitated 
by Boyden's micropore filter technique, which enables one to 
perform analytic measurement of chemoattractants far more ac­
curately than the previous in vitro methods. Later, an agarose 
assay was developed, another efficient method (4). Both methods 
in principle measure quantitatively either the number of cells 
migrated or the distance of their migration after a certain period 
of incubation. Thereby, a distinction can be made between che­
motactic responses, which result in directional locomotion to a 
gradient source of chemicals, and chemokinetic reactions, in which 
environmental stimuli cause cells to move faster or slower at 
random. 
Does Psoriatic Scale Show Chemotactic Properties? In 1966, 
Langhof and Muller (5) documented that human peripheral blood 
leukocytes migrated toward homogenates of psoriasis scales in 
plasma; they used a classic slide-and-coverslip preparation. They 
described a peculiar finding that is unexplainable today, i.e., the 
homogenates became chemotactically inert when the acidity was 
neutralized. No further information was available as to whether 
this chemotactic property of horny tissues are only specific for 
psoriatic scale, or whether plasma is required for the scale extract 
to manifest the chemotactic effect by activation of the complement 
system. They did not extend their investigation nor did other 
researchers pay special attention to this aspect of psoriasis at that 
time. 
Only after a subsequent lapse of 10 years we started systematic 
analytic studies on the chemotactic properties of water-soluble 
substances in psoriasis scales using a modified Boyden's chamber 
(6). We found that the psoriatic scale extracts were chemotactic 
for human neutrophils in the absence of plasma and serum, like 
other crude horny tissue extracts, including that from normal 
skin. The activity was retained even at neutral pH, as against the 
report by Langhof and Miiller [5). 
Because bacteria release potent neutrophil chemotactic pep tides 
with their growth [4) and the skin, particularly that of scaly 
lesions, carries its resident microbial flora on its surface, we must 
take the possibility of contamination by bacterial chemotactic 
factors into account whenever we discuss the data obtained from 
such materials. In psoriatic scale extract, Dahl et al [7) demon­
strated chemokinetic property in addition to chemotactic activity 
for PMN and mononuclear cells. Liden et al [8) confirmed these 
properties and found no migration-stimulating activity in the 
extract of perilesional uninvolved skin. According to Dahl et al 
(7J the chemokinetic property was more like that of a bacteria-
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Figure 1. a, Leukocytes adhere to the SC in the psoriatic lesions, showing 
vigorous incorporation of blackish crystals of formazan converted from 
nitroblue tetrazoliun dyes (arrows). b, The result of the nitroblue tetra­
zolium test carried out on the serially sectioned biopsy specimens is found 
to be negative, which shows the specificity of the feature of a. c, Deposits 
of complement (C3) are constantly observable at the SC in the same biopsy 
specimens. 
culture supernatant than that of complement-derived chemotactic 
factor. This suggests that crude psoriatic scales contain large 
amounts of bacterial chemotactic factor. 
Nevertheless, the neutrophil chemotactic activity of the pso­
riatic scale extract is highly potent compared with those of other 
scaly inflammatory dermatoses (6). P ityriasis rubra pilaris (P RP ) 
constitutes an ideal control for such study, because P RP lesions 
totally lack the transepidermal leukocyte migration toward the 
horny layer, as noted in psoriasis, although it is characterized by 
scaly erythematous plaques associated with hyperproliferative 
epidermis. By comparison, the psoriatic scale extract showed 
much higher chemotactic activity than that ofP RP (Fig 2), sug­
gesting that there are some potent chemotactic factors in the 
lesional horny layer of psoriasis other than bacterial chemotactic 
factors and endogeneous chemical mediators common to cuta­
neous inflammation. This can be ascertained by determining the 
chemotactic potency demonstrable in fractions of different mo­
lecular mass prepared from the psoriatic scale extracts. 
What Kind of Potent Chemotactic Substances Does Pso­
riasis Scale Specifically Contain? By gel filtration chroma­
tography, the scale extracts from psoriasis vulgaris and pustular 
psoriasis consistently showed potent chemotactic activity eluting 
near the cytochrome c molecular mass marker (12.5 kD), in ad­
dition to a multiphasic chemotactic pattern [6). Although mod­
erate chemotactic activity was also noted in the same eluate of 
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the scale extract from nonpsoriatic dermatitis, it was much weaker 
than that of psoriasis. Later study ruled out the possibility that 
this unique chemotactic fraction from the psoriatic scale extract 
was contaminated by keratinization metabolites, bacterial che­
motactic factors, or by plasma exudation [9,10]. Among known 
endogenous chemotactic factors, cleavage fragments ofC5 (C5fr), 
either C5a or C5a des arg came out as the most probable active 
substances contained in this fraction. In fact, complement-acti­
vated serum by zymosan that contains C5fr revealed chemotactic 
activity of similar molecular mass [10]. 
Further characterization of this chemotactic fraction, which was 
called psoriatic leukotactic factor (PLF) , contained active pep­
tide(s) resistant to heating 100°C for 10 min, lyophilization, ac­
idity (pH 3) and alkalinity (pH 11), but was inactivated by trypsin 
digestion [9]. 
A checkerboard analysis, which was set up to determine whether 
PLF is chemotactic or chemokinetic for neutrophils by system­
atically varying the concentration of PLF on both sides of the 
Millipore filters, demonstrated that PLF had a chemokinetic effect 
on neutrophils, although very weak when compared with the 
prominent chemotactic effect [10]. The chemotactic response to 
PLF was noted with neutrophils derived from humans, rabbit, 
and guinea pigs. Despite the strong chemotactic activity for neu­
trophils, PLF was mildly chemotactic for mononuclear cells [9], 
and totally lacked chemotactic activity for eosinophils [11]. 
Intradermal injection of PLF into human skin produced an 
erythematous response with dense tissue neutrophilia, the time 
course of which was similar to that of the Arthus response. In 
guinea pig skin, PLF was found to enhance vascular permeability 
[9]. 
Can We Find Similar Chemotactic Factors in Other Der­
matoses Characterized by Sterile Subcorneal Pustules? 
Characterization of the chemotactic activity in crude extracts from 
the lesional horny layer ofPPP by gel filtration showed the pres­
ence of fractions eluting near the cytochrome c marker and ex­
hibiting the same in vitro and in vivo biologic activities as those 
of PLF [12]. Moreover, we had a chance to study a 50-year-old 
female patient with SPD who developed numerous tense or flaccid 
vesiculo-bullous lesions on the trunk at the active stage [13]. 
Fractionation of the soluble components in the scale extract re­
vealed a multiphasic pattern of chemotactic activity similar to 
those from pustular psoriasis and PPP, with a definite peak of 
PLF. However, it is of note that fractionation of the vesicle con­
tent performed in the same way demonstrated only the presence 
ofPLF, suggesting that other chemotactic substances noted in the 
scale extracts are secondary contaminants of scales, playing only 
a minor role in the formation of the sterile subcorneal pustules. 
Likewise, we found a similar chemotactic fraction in the scale 
extract of pustulosis vegetans [14], a tentatively designated name 
for a disorder showing sterile pustules and crusted vegetative 
plaques on the trunk and limbs, which left cribriform scars after 
healing, and in the scale extract of palmo-plantar pustular lesions 
of EPF [15]. 
Are Complement Fragments Contained in PLF? Because 
various complement-derived anaphylatoxins, C3a, C4a, and C5a, 
as well as their corresponding des arg derivatives, which are only 
devoid of C-terminal arginine by the action of serum carboxy­
peptidase N (in this article all of them are collectively called as 
C3a, C4a, and C5a for simplicity), share similar molecular mass, 
it is probable that they coexist in PLF. The presence of C3a, 
which induces vasodilatation and increases vascular permeability, 
could be demonstrated by immunodiffusion in PLF prepared from 
pustular psoriasis [16]. 
C5fr constitute major biologically active chemotactic anaphy­
latoxins [17] and the neutrophil chemotactic activity of PLF was 
partially inhibited either by antiserum to C5 [9]. Purification of 
PLF according to the isolation procedure for C5a anaphylatoxin 
yielded a cationic peptide fraction similar to the reported char­
acteristics of C5a, suggesting that at least a part of PLF consists 
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Figure 2. Comparison of neutrophil chemotactic activity demonstrable 
in the scale extract psoriasis vulgaris (open circle) and that of pityriasis 
rubra pilaris (open triangle). Mean values of triplicate measurements and 
standard deviations (bars). 
of C5fr [10]. As freshly generated C5a is rapidly converted to 
C5a des arg unless there is an inhibitor of serum carboxypeptidase 
N, presumably the latter may make up the predominant form in 
PLF; C5a des arg is spasmogenically inactive but is chemotacti­
cally potent, though much weaker than C5a [17]. Recently, Schroder 
and Christophers [18] confirmed the predominance of C5a des 
arg in scale extracts. Our determination of C3a, C4a, and C5a 
levels by radioimmunoassay have demonstrated a larger amount 
of these anaphylatoxins in scale extracts of psoriasis and related 
pustular dermatoses than in those of noninflammatory stratum 
corneum [19]. The levels of C5a showed a significant correlation 
with the PMN chemotactic activity demonstrable in the crude 
scale extracts (p < 0.005). 
How is Complement Activated in Lesional Skin? Beutner 
et al [20] demonstrated linear deposits of immunoglobulins and 
complement in virtually all psoriatic lesional horny layers and 
implicated autoimmune responses between stratum corneum (SC) 
and anti-stratum corneum antibody (SC-Ab) for the activation 
of complement. S ince the stratum corneum, the formation of 
which is beyond the limits of immune surveillance, is foreign to 
the body, SC-Ab are demonstrable in almost all human sera [21]. 
Using autologous normal skin and freshly separated sera we 
found that the titers of circulating anti-SC IgG autoantibodies 
and those of complement-fixing anti-SC autoantibodies were not 
specifically higher in psoriatic patients than in those with non­
psoriatic inflammatory dermatoses or in normal controls [22]. 
This constitutes a striking contrast to other autoimmune dieases 
such as SLE, pemphigus, and bullous pemphigoid, in which the 
patients show specifically high titers of respective autoantibodies. 
Our results imply that if SC-Ab really take part in the patho­
genesis of psoriatic lesions, a local factor in psoriatic epidermis 
that may provide favorable conditions for the occurrence of an 
autoimmune reaction by facilitating the permeation of SC-Ab to 
the horny layer and by uncovering the hidden SC antigen even 
, affer a trivial trauma may play a much more crucial role than the 
level of circulating antibodies. In contrast to psoriasis, SC-Ab 
were found with higher titers in patients with PPP [23]. 
Complement activation via the alternative pathway was also 
suggested based on the data from immunohistologic or serologic 
study [24,25]. In contrast, Lazarus et al [26] demonstrated cleavage 
of C5 by serine proteinase derived from lesional epidermis, sug­
gesting nonimmunologic production of C5fr. The histochemical 
study by Dubertret et al [27] on autolyzing skin showed that even 
nonlesional psoriatic epidermis was rich in serine proteinase as 
compared with nonpsoriatic epidermis, whereas Glinski et al [28] 
stressed the importance of enzymes released from migrating PMN 
that contributed to such properties of lesional epidermis as well 
as revealing the hidden SC antigen. 
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Do Other Chemotactic Pep tides Exist in PLF? Goat anti­
CS antiserum can inhibit only partially the activity ofPLF [9]. If 
the major component of PLF is composed of C5fr, it should be 
inhibited by anti-C5 antiserum, as is the case with zymosan­
activated serum. We have found that treatment ofPLF with rabbit 
anti-C5a antiserum, a gift from Dr. T. E. Hugli (Scripps Clinic 
and Research Foundation, La Jolla, California), induced only par­
tial inhibition of its chemotactic activity in scale extracts prepared 
from above mentioned dermatoses [29]. These findings suggest 
that chemotactic pep tides other than C5fr are also present in PLF. 
Interleukin 1 [IL-l] is the most plausible candidate. Interleukin 
1 is a macrophage-produced peptide that exerts a number of im­
munostimulatory and inflammatory effects, including neutrophil 
chemotactic activity. In psoriatic lesions there is always a mono­
nuclear cell infiltrate consisting of T lymphocytes and mono­
nuclear phagocytes; hence, possible implications of cellular im­
mune mechanisms [30] or altered monocyte function [31] have 
been suggested in regard to pathomechanisms of psoriasis. Fur­
thermore, epidermal keratinocytes have been shown to elaborate 
epidermal cell-derived thymocyte-activating factor (ET AF), which 
has many similarities to IL-l, sharing common physicochemical 
and biologic properties, and a molecular mass of around 15 kD 
[32]. We must also consider that an IL-l-like factor may be produced 
even by infiltrating PMN [33]. 
Recently, chemokinetic polypeptides resembling IL-l [34] have 
been reported to be detected in psoriatic scales. We have also 
demonstrated IL-l activity in one sample of PLF prepared from 
scales of psoriasis vulgaris [29]. However, we are reluctant to 
conclude that there is IL-l or ETAF, other than C5fr, which 
might contribute to the chemotactic activity ofPLF in every case, 
because our screening failed to detect IL-l activity in most of the 
crude scale extract prepared from psoriasis and related pustular 
dermatoses, in contrast to rather high amounts demonstrable in 
horny tissue extract prepared from noninflammatory skin [35]. 
Furthermore, IL-l is not heat-stable [32], in contrast to PLF. 
Recently, Schroder and Christophers [18] demonstrated the pres­
ence of an anionic neutrophil-activating peptide (A NAP) in ad­
dition to C5a des arg in psoriatic scale extracts; they found that 
ANAP cross-reacted with the chemotactic factor derived from 
monocytes, such as the one described by Kownatzki et al [36], 
which showed prominent heat stability and a molecular mass of 
10 kD. 
In a different approach, Ohtani et al [37] suggested a less ef­
fective natural anti-inflarnmatory substance as being partly re­
sponsible for psoriatic inflammation, based on the decreased in­
hibitor activity of epidermal thiol proteinase in psoriatic scales. 
Are Potent Chemotactic Factors Other Than Pep tides Con­
tained in Psoriatic Lesions? Various investigators have sug­
gested that the PMN migration in psoriatic lesions may be due 
to acidic lipid chemotactic factors, particularly cell mem­
brane-derived arachidonic acid metabolites, based on highly el­
evated cellular content of free arachidonic acid and 12-hydroxy­
eicosatetraenoic acid probably produced as a result of increased 
phospholipase A2 activity in involved psoriatic epidermis [38-40]. 
Among them, leukotriene B4 (LTB4), the most potent lipid che­
moattractant of the 5-lipoxygenase products, was identified in 
chamber fluid from psoriatic skin lesions [41], whole skin extracts 
of psoriatic lesions, as well as in the scales overlying involved 
skin [42,43]; it was increased even in the extract of uninvolved 
psoriatic skin [43]. However, because psoriatic plaques contain 
variable numbers of PMN, which are a rich source of L TB4, it 
is difficult to say whether the elevated 5-lipoxygenase 
and LTB4 in plaques is produced by PMN, the epidermis, or 
both. Moreover, the increase of LTB4 is not specific to psoriasis. 
It is also increased in the lesions of allergic contact dermatitis [44], 
atopic dermatitis [45], and P RP [46]; we can not find PMN as a 
major inflammatory infiltrate in any of these. Although these 
[mdings cast doubt about its specificity in psoriasis, they do not 
rule out the proinfiammatory role of L TB4 in the production of 
psoriatic lesions. 
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Our quantification of the levels of L TB4 in ether extracts (pH 
3) from psoriasis and related pustular dermatoses using radioim­
munoassay [47] also showed an increased amount of LTB4 in scale 
extracts from psoriasis and related pustular dermatoses. However, 
the L TB4 levels correlated poorly with the chemotactic activity 
demonstrable in the crude scale extracts; the chemotactic activity 
showed a much more significant correlation with the contents of 
C5a that was measured by radioimmunoassay. 
As another lipid mediator, Mallet and Cunningham [48] de­
tected the presence of platelet activating factor (P AF-acether) in 
the lesional scale of psoriatic patients, which has potent proin­
flammatory properties as a vasodilator, permeability-increasing 
agent, and chemoattractant. It is a second messenger produced 
by inflammatory cells by the action of phospholipase A2, and it 
activates PMN. However, no data is available on whether P AF­
acether is specifically rich in psoriasis compared with other in­
flammatory dermatoses. Our recent study disclosed that low mo­
lecular mass chemotactic lipid fractions from psoriatic scale ex­
tracts that should contain both L TB4 and P AF-acether were far 
less effective in stimulating the generation of toxic oxygen radicals 
in PMN than was the PLF fraction, ruling out their predominant 
role in the production of damage in the lesional epidermis, which 
may culminate in the induction of the enhanced epidermopoiesis 
and keratinization disorder in psoriatic lesions (our unpublished 
data). 
What are the Functional Properties of Circulating Leuko­
cytes of Psoriatic Patients? Circulating PMN from patients 
with active psoriasis have been reported to show increased activ­
ities in chemotactic response to chemoattractants [6,49-51], ad­
herence to plastic or to human endothelium [52], phagocytosis 
[49], generation of superoxide radicals [53], chemoluminescence 
[54], neutral proteinases [28], and in liberation of enzymes [51]. 
In contrast, other investigators could find no such increased 
functions in PMN from patients with psoriasis [55-57]. These 
PMN functions should probably have been studied in correlation 
with the inflammatory activity of the disease, because even one 
of the latter groups [57] noted more active chemotactic responses 
in PMN derived from patients with pustular psoriasis than in 
those from patients with ordinary psoriasis. 
Do Psoriatic Sera Contain Chemical Mediators of Inflam­
mation? One of the reasons for enhanced activities of psoriatic 
PMN seems to be that the sera from psoriatic patients contain 
substances that strongly affect the function of normal human 
PMN as shown for chemotaxis, chemokinesis, adherence, and 
superoxide anion generation [52,53,55]. These properties of pso­
riasis sera appear to depend primarily on the products of the 
activated complement system. We found increased serum levels 
of CSa as well as C3a and C4a in psoriatic sera [58,59]. Although 
there were great intersubject variations, their levels decreased with 
clinical improvement of skin lesions when a comparison was made 
in the same group of patients. 
S ince heat inactivation of the sera abolishes the enhancing effect 
on chemotaxis by nearly 50% [49], some heat-labile factor other 
than complement components, which are heat-stable, could be 
responsible for the increased PMN adherence and partially for the 
enchancement of the chemotaxis. As there is an elevation of pro­
teases generated by PMN in the active stages of psoriasis [52], it 
is possible that liberated proteolytic enzymes are responsible for 
the observed increase of PMN functions. 
What Initiates and What Terminates the PMN Migration? 
Chowaniec et al [60] reported that there was PMN infiltration 
into epidermis with immune deposits in SC in very early spotty 
erythematous lesions of psoriasis that might develop into pinpoint 
lesions; thus, they called them prepinpoint lesions. On the other 
hand, Ragaz and Ackerman [61] observed only mononuclear cells 
in such lesions. Likewise, in experimental production of psoriatic 
plaques after stripping noninvolved skin of psoriatic patients, 
neutrophilic response occurs late in the sequence of events in the 
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formation of the psoriatic lesion, one week after the invasion of 
activated lymphocytes into the epidermis [62]. The findings of 
Johannesson et al [63] that hyperproliferative changes of the epi­
dermis preceded the appearance of immunodeposits by one to 
several days, also suggest a foregoing inflammatory event that 
enhances epidermopoiesis. Meanwhile, in a time-course study in 
the lesions ofPPP, Uehara and Ofuji [64] observed that spongiotic 
epidermal change with exocytosis of mononuclear cells precedes 
the formation of subcorneal pustules. In such cases it is plausible 
that the mononuclear cells may play a role in initiating the trans­
epidermal PMN migration by secreting chemotactic factors them­
selves, by damaging the epidermal tissue to facilitate the exudation 
of serum toward SC, or by affecting the keratinocytes to induce 
secondary release of cell-derived lipid chemotactic factors. 
As is presumed from the descriptive term "squirting papillae," 
the PMN migration does not persist but repeats cyclically [1]. 
However, nothing is known about the mechanism( s) that ter­
minates this chemotactic event. Only serum IgA has been sug­
gested by Christophers and Schroder [65] to exert modulating 
influences on PMN chemotaxis. IgA is presumed to be present 
in psoriatic epidermis from the study of Kaneko et al [66], who 
demonstrated IgG-IgA immune complexes in psoriatic scales. 
How do the Therapeutic Agents for Psoriasis Exert an In­
fluence on PMN Chemotaxis? Finally, a brief mention is made 
of the treatment of psoriasis from the viewpoint of PMN che­
motaxis. Most drugs that influence PMN function are effective 
for the treatment of psoriasis. For example, colchicine [67], meth­
otrexate [68], etretinate [69], and anthralin [70] inhibit PMN che­
motactic function. PUV A inactivates P LF and anaphylatoxins 
[71,72], while corticosteroids and benoxaprofen inhibit the pro­
duction of L TB4 by suppressing arachidonate metabolism [73]. 
CONCLUSION 
The lesional epidermis of psoriasis contains various chemical me­
diators, such as complement-derived anaphylatoxins, arachidonic 
acid metabolites, P AF-acether, monokines, and bacterial che­
motactic factors, which may have complex synergistic or possibly 
antagonistic action to produce its most characteristic feature, 
trans epidermal migration of leukocytes. However, we still do not 
know what kind of chemotactic factor plays a major role in the 
initiation of leukocyte chemotaxis, what sustains such responses 
to induce the epidermal damage, and what terminates this tran­
sient discharge phenomenon of inflammatory cells and serum 
components into the lesional epidermis. Clearly much research 
has to be done in this area. Most of all it is hoped that a much 
fuller understanding of the immunoregulatory mechanisms un­
derlying these specific inflammatory changes will direct us to 
more effective therapy of psoriasis. 
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